World Health Organization Sounds Warning Over Critical Scarcity of Weight-Loss Jabs
Under a tenth of people eligible to benefit from obesity jabs including Wegovy are able to get them, warns the WHO as it publishes its first guidance on the medications.
With more than one billion people worldwide currently living with obesity, it is urging more widespread and fairer access to GLP-1 medication.
Per projections, over two billion will be living with obesity by 2030 if no action is taken.
"The new guidance acknowledges that excess weight is a lifelong illness that can be managed with holistic and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant hurdles to universal availability to the treatments that can aid individuals in losing considerable weight, notes the body.
Skinny Jab Supply Crisis
Despite the present most favorable scenario, the manufacturing of such drugs could only cover about 100 million people – under 10% of eligible patients, per the WHO.
The recommendation urges countries and companies to widen availability, through approaches such as patent sharing.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Injections Work
These medications replicate a natural hormone to delay gastric emptying, curb appetite and enhance the sense of being full so individuals eat less.
People typically begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Evidence suggests users may see weight return after a year of stopping the medication, when their normal hunger resume.
Being carrying excess weight increases your chance for contracting medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight concerns people in all nations and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
